Hospital
Self Regional Healthcare
Self Regional Healthcare was paid $58.94M by Medicaid between Jan 2018 and Dec 2024, across 441 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 13% of everything it billed.
33Billing provider infoSELF REGIONAL HEALTHCARE
GREENWOOD, SC 29646
GREENWOOD, SC 29646
33aNPI1407887003assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$58.94M
24GClaims1,617,780
24DCodes billed441
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#6 of 115
Median peer was paid$2.47M
This provider vs. median24×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LOGAN, MATTHEW controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 198,540 | $6.06M | |
| 2019 | 183,328 | $6.29M | |
| 2020 | 221,552 | $8.90M | |
| 2021 | 275,638 | $10.16M | |
| 2022 | 274,643 | $12.01M | |
| 2023 | 258,794 | $9.30M | |
| 2024incomplete | 205,285 | $6.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 19,049 | 14,855 | $7.39M |
| 36415 | Collection of venous blood by venipuncture | 9.6% | 60,306 | 42,706 | $5.68M |
| 80053 | Comprehensive metabolic panel | 6.7% | 66,140 | 53,394 | $3.96M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.6% | 28,088 | 17,982 | $3.30M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 47,226 | 11,922 | $2.37M |
| 76376 | 3.5% | 20,959 | 18,730 | $2.04M | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.4% | 32,159 | 25,191 | $2.00M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 8,163 | 6,535 | $1.92M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.1% | 13,478 | 12,284 | $1.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 31,777 | 29,587 | $1.36M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.1% | 17,988 | 4,887 | $1.24M |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.9% | 1,483 | 1,436 | $1.12M |
429 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 5,240 | $1.01M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.7% | 2,068 | $1.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 8,707 | $927K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 4,892 | $696K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 27,991 | $691K |
| 82565 | 1.1% | 1,773 | $669K | |
| 81025 | 1.0% | 16,930 | $593K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 371 | $544K |
| 72141 | <1% | 921 | $541K | |
| 93922 | <1% | 2,148 | $509K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,218 | $440K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,670 | $439K |
| 93971 | <1% | 1,810 | $439K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 753 | $431K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,628 | $426K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,561 | $416K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,364 | $389K |
| 81001 | <1% | 30,745 | $382K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 20,858 | $356K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,159 | $341K |
| 86900 | <1% | 3,456 | $326K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,981 | $311K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 10,803 | $303K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15,669 | $302K |
| 93880 | <1% | 1,347 | $293K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,504 | $283K |
| 82962 | <1% | 18,708 | $280K | |
| 99284 | Emergency room visit (serious) | <1% | 26,044 | $277K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,316 | $264K |
| 94060 | <1% | 728 | $248K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,367 | $242K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,059 | $235K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,333 | $217K |
| 93225 | <1% | 676 | $206K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 906 | $197K |
| 73610 | <1% | 2,538 | $188K | |
| 93017 | <1% | 2,063 | $182K | |
| 87081 | <1% | 5,614 | $181K | |
| 94010 | <1% | 1,991 | $175K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,041 | $169K |
| 87077 | <1% | 6,527 | $164K | |
| 73130 | <1% | 2,189 | $157K | |
| 77062 | <1% | 866 | $153K | |
| 73564 | <1% | 3,358 | $153K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,787 | $150K |
| 73030 | <1% | 2,383 | $149K | |
| 95886 | <1% | 1,065 | $146K | |
| 73630 | <1% | 3,294 | $145K | |
| 93970 | <1% | 767 | $137K | |
| 72040 | <1% | 2,071 | $134K | |
| 97161 | <1% | 4,573 | $133K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 89,682 | $133K |
| 76830 | Ultrasound, transvaginal | <1% | 1,662 | $132K |
| 73110 | <1% | 1,479 | $132K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,065 | $131K |
| 81003 | <1% | 7,183 | $123K | |
| 87210 | <1% | 2,662 | $123K | |
| 74018 | <1% | 2,870 | $122K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,629 | $118K |
| 72100 | <1% | 3,336 | $118K | |
| 84702 | <1% | 3,020 | $118K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,941 | $112K |
| 0001A | <1% | 1,648 | $103K | |
| 87070 | <1% | 3,413 | $101K | |
| G0378 | Hospital observation service, per hour | <1% | 18,821 | $96K |
| 73221 | <1% | 164 | $96K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,613 | $96K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 27,737 | $92K |
| 0002A | <1% | 1,526 | $90K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,739 | $89K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,895 | $88K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,144 | $87K |
| 86780 | <1% | 4,064 | $86K | |
| 82803 | <1% | 1,976 | $86K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,387 | $82K |
| 76536 | <1% | 1,066 | $82K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,013 | $80K |
| 93270 | <1% | 338 | $80K | |
| 76775 | <1% | 1,189 | $77K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,804 | $75K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,563 | $72K |
| 71250 | <1% | 1,628 | $72K | |
| 92523 | <1% | 612 | $72K | |
| 99285 | Emergency room visit (most serious) | <1% | 29,046 | $71K |
| 76377 | <1% | 584 | $71K | |
| 74022 | <1% | 3,506 | $69K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,418 | $69K |
| 77061 | <1% | 430 | $67K | |
| 73090 | <1% | 672 | $64K | |
| J3490 | Unclassified drugs | <1% | 27,867 | $64K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,853 | $63K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,590 | $63K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,315 | $63K |
| 97162 | <1% | 2,926 | $62K | |
| 80074 | <1% | 1,274 | $60K | |
| 76642 | <1% | 1,788 | $59K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,147 | $58K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 20,090 | $57K |
| 72120 | <1% | 539 | $56K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 455 | $56K |
| 96367 | <1% | 664 | $55K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 407 | $51K |
| 73140 | <1% | 342 | $51K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,381 | $50K |
| 73502 | <1% | 1,605 | $50K | |
| 80061 | Lipid panel | <1% | 16,241 | $48K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 178 | $47K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,702 | $47K |
| 36600 | <1% | 900 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,816 | $45K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 371 | $45K |
| 73080 | <1% | 475 | $44K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,447 | $44K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,011 | $40K |
| 73590 | <1% | 885 | $40K | |
| 83655 | <1% | 3,272 | $39K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,602 | $39K |
| 77336 | <1% | 181 | $39K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 1,962 | $38K |
| 85027 | <1% | 9,695 | $37K | |
| 97113 | <1% | 1,177 | $36K | |
| 64483 | <1% | 1,713 | $33K | |
| 87428 | <1% | 400 | $33K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 8,016 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,370 | $31K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 123 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,280 | $30K |
| 85018 | <1% | 2,757 | $29K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,006 | $29K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,138 | $28K |
| 85610 | <1% | 14,405 | $27K | |
| 80081 | <1% | 227 | $26K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 7,062 | $26K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,767 | $24K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 717 | $24K |
| 88300 | <1% | 1,538 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,693 | $24K |
| 88304 | <1% | 1,381 | $24K | |
| 88142 | <1% | 2,527 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,936 | $23K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 64 | $22K |
| 72070 | <1% | 613 | $22K | |
| 12001 | <1% | 184 | $22K | |
| 84439 | <1% | 4,758 | $22K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,790 | $21K |
| 87807 | <1% | 967 | $21K | |
| 93246 | <1% | 214 | $20K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,117 | $20K |
| 76801 | <1% | 662 | $20K | |
| 94760 | <1% | 4,447 | $19K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 783 | $19K |
| 81000 | <1% | 2,209 | $19K | |
| 76641 | <1% | 630 | $19K | |
| 84112 | <1% | 157 | $18K | |
| 72158 | <1% | 41 | $18K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,344 | $17K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 125 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,074 | $16K |
| 10035 | <1% | 179 | $16K | |
| 82570 | <1% | 4,333 | $16K | |
| 82247 | <1% | 684 | $15K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,690 | $15K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,005 | $15K |
| 97164 | <1% | 1,834 | $15K | |
| 86592 | <1% | 1,017 | $15K | |
| G0008 | Administration of influenza virus vaccine | <1% | 536 | $14K |
| 82728 | <1% | 4,871 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,466 | $14K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 824 | $14K |
| 83735 | <1% | 27,468 | $14K | |
| 94664 | <1% | 5,827 | $13K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,578 | $13K |
| A4217 | Sterile water/saline, 500 ml | <1% | 90 | $13K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 171 | $13K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,744 | $13K |
| 93925 | <1% | 291 | $13K | |
| 97166 | <1% | 730 | $12K | |
| 97165 | <1% | 844 | $12K | |
| 86850 | <1% | 2,955 | $12K | |
| 93458 | <1% | 14 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,364 | $11K |
| 85730 | <1% | 13,009 | $11K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,013 | $11K |
| 95806 | <1% | 102 | $11K | |
| 97116 | <1% | 4,308 | $11K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,232 | $11K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,794 | $11K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,955 | $11K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,471 | $10K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 364 | $10K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,343 | $10K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 82 | $10K |
| 82607 | <1% | 3,147 | $10K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 255 | $10K |
| 99152 | <1% | 602 | $10K | |
| 83540 | <1% | 5,559 | $9K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 472 | $9K |
| 0004A | <1% | 235 | $9K | |
| 86140 | <1% | 3,986 | $9K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,123 | $9K |
| 84484 | <1% | 22,351 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 186 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,641 | $8K |
| 93990 | <1% | 38 | $8K | |
| 11719 | <1% | 347 | $8K | |
| 73552 | <1% | 362 | $8K | |
| 72110 | <1% | 88 | $8K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 129 | $8K |
| 80076 | <1% | 2,514 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 88 | $8K |
| 87045 | <1% | 257 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 363 | $7K |
| 86901 | <1% | 3,771 | $7K | |
| 82043 | <1% | 1,226 | $7K | |
| 81002 | <1% | 578 | $7K | |
| 87205 | <1% | 2,884 | $7K | |
| 87280 | <1% | 60 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,245 | $7K |
| 86038 | <1% | 1,158 | $7K | |
| 87040 | <1% | 6,802 | $6K | |
| 77065 | Tomosynthesis, mammo | <1% | 536 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 921 | $6K |
| 74220 | <1% | 143 | $6K | |
| 80055 | <1% | 29 | $6K | |
| 96523 | <1% | 709 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,116 | $6K |
| 84145 | <1% | 1,079 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,455 | $6K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,233 | $5K |
| 85379 | <1% | 3,151 | $5K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,944 | $5K |
| 0072A | <1% | 110 | $5K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 915 | $5K |
| 71101 | <1% | 97 | $4K | |
| 84466 | <1% | 4,962 | $4K | |
| 83605 | <1% | 6,021 | $4K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 697 | $4K |
| 84153 | <1% | 759 | $4K | |
| 84156 | <1% | 3,042 | $4K | |
| 82731 | <1% | 67 | $4K | |
| 10060 | <1% | 30 | $4K | |
| 87046 | <1% | 269 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,001 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 134 | $4K |
| 76942 | <1% | 1,057 | $4K | |
| 80051 | <1% | 771 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,345 | $4K |
| 0054A | <1% | 106 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,272 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,416 | $4K |
| 90715 | <1% | 1,576 | $4K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 46 | $4K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,750 | $4K |
| 93242 | <1% | 57 | $4K | |
| 71271 | <1% | 12 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 396 | $4K |
| 0071A | <1% | 85 | $3K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 83 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 187 | $3K |
| 80305 | <1% | 49 | $3K | |
| 93926 | <1% | 39 | $3K | |
| 84550 | <1% | 1,974 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,085 | $3K |
| 73060 | <1% | 55 | $3K | |
| 62321 | <1% | 56 | $3K | |
| 90686 | <1% | 735 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,568 | $3K |
| 82140 | <1% | 477 | $3K | |
| 82550 | <1% | 3,174 | $3K | |
| 76882 | <1% | 38 | $2K | |
| 78227 | <1% | 12 | $2K | |
| 83880 | <1% | 3,494 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 392 | $2K |
| 83690 | <1% | 12,437 | $2K | |
| 70360 | <1% | 40 | $2K | |
| 95911 | <1% | 71 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 17 | $2K |
| 86803 | <1% | 2,741 | $2K | |
| 20611 | <1% | 68 | $2K | |
| 82950 | <1% | 213 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 163 | $2K |
| 84100 | <1% | 3,774 | $2K | |
| 72170 | <1% | 137 | $2K | |
| 76857 | <1% | 671 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 266 | $1K |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 54 | $1K |
| 96376 | <1% | 3,448 | $1K | |
| 86762 | <1% | 160 | $1K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 662 | $1K |
| 70486 | <1% | 158 | $1K | |
| 82785 | <1% | 31 | $1K | |
| 0052A | <1% | 42 | $1K | |
| 93325 | <1% | 59 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 55 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 487 | $1K |
| 87641 | <1% | 304 | $1K | |
| 88173 | <1% | 12 | $1K | |
| 82077 | <1% | 3,332 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 754 | $1K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 41 | $989.60 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,061 | $941.12 |
| 64493 | <1% | 125 | $918.20 | |
| 74178 | <1% | 14 | $856.37 | |
| 73560 | <1% | 62 | $829.31 | |
| 83001 | <1% | 14 | $799.07 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 18 | $796.92 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 23 | $756.63 |
| 0051A | <1% | 20 | $673.12 | |
| 83970 | <1% | 1,998 | $662.64 | |
| 93976 | <1% | 44 | $636.65 | |
| 70491 | <1% | 92 | $635.82 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 12 | $615.45 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 178 | $583.20 |
| 27096 | <1% | 12 | $574.18 | |
| 93247 | <1% | 16 | $565.25 | |
| 96161 | <1% | 15 | $522.00 | |
| 94726 | <1% | 90 | $492.82 | |
| 84132 | <1% | 28 | $487.47 | |
| 59025 | Fetal non-stress test | <1% | 72 | $471.35 |
| 86580 | <1% | 58 | $462.30 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 169 | $457.37 |
| 96127 | <1% | 14 | $392.00 | |
| 82784 | <1% | 91 | $362.15 | |
| 84480 | <1% | 2,884 | $337.64 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 539 | $306.11 |
| 85652 | <1% | 5,173 | $305.59 | |
| 82150 | <1% | 315 | $269.35 | |
| 84146 | <1% | 16 | $250.05 | |
| 36591 | <1% | 76 | $242.10 | |
| 82652 | <1% | 20 | $225.58 | |
| 92610 | <1% | 15 | $220.22 | |
| 86003 | <1% | 102 | $215.60 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $208.46 |
| 70496 | <1% | 13 | $203.87 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,736 | $198.35 |
| 84403 | <1% | 74 | $169.68 | |
| 82553 | <1% | 2,019 | $168.78 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 26 | $144.15 |
| 84681 | <1% | 124 | $138.14 | |
| 87186 | <1% | 5,962 | $122.47 | |
| 84703 | <1% | 13 | $113.46 | |
| 86141 | <1% | 414 | $111.06 | |
| 88160 | <1% | 13 | $92.08 | |
| 88342 | <1% | 149 | $86.21 | |
| 88307 | <1% | 49 | $78.77 | |
| 82105 | <1% | 12 | $63.31 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,194 | $38.13 |
| 90656 | <1% | 15 | $37.15 | |
| 86334 | <1% | 187 | $32.86 | |
| 83615 | <1% | 862 | $27.66 | |
| 74019 | <1% | 17 | $26.91 | |
| 87088 | <1% | 46 | $23.09 | |
| 99188 | <1% | 328 | $20.00 | |
| 82746 | <1% | 1,448 | $18.95 | |
| 86317 | <1% | 14 | $16.89 | |
| 84155 | <1% | 285 | $16.10 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 412 | $11.88 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 149 | $10.32 |
| 87340 | <1% | 481 | $9.83 | |
| 82248 | <1% | 750 | $6.79 | |
| C1769 | Guide wire | 0% | 1,433 | $0.00 |
| A9270 | Non-covered item or service | 0% | 108 | $0.00 |
| 36430 | 0% | 124 | $0.00 | |
| 82330 | 0% | 1,128 | $0.00 | |
| 86160 | 0% | 14 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 544 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 327 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 247 | $0.00 |
| 86225 | 0% | 12 | $0.00 | |
| 64494 | 0% | 108 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 303 | $0.00 |
| 88341 | 0% | 26 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 70 | $0.00 |
| 76982 | 0% | 112 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 198 | $0.00 |
| 83883 | 0% | 39 | $0.00 | |
| 83521 | 0% | 150 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 60 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 28 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 76 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 15 | $0.00 |
| 87536 | 0% | 51 | $0.00 | |
| 82378 | 0% | 30 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 45 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 46 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 12 | $0.00 |
| 96368 | 0% | 18 | $0.00 | |
| 64484 | 0% | 14 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 28 | $0.00 |
| 96411 | 0% | 19 | $0.00 | |
| 94762 | 0% | 22 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 13 | $0.00 |
| 86376 | 0% | 12 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 13 | $0.00 |
| 94660 | 0% | 70 | $0.00 | |
| 84165 | 0% | 297 | $0.00 | |
| 85045 | 0% | 326 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 748 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| 94729 | 0% | 546 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 16 | $0.00 |
| 76937 | 0% | 44 | $0.00 | |
| 96417 | 0% | 202 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 55 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 818 | $0.00 |
| A9505 | Thallium tl-201 thallous chloride, diagnostic, per millicurie | 0% | 151 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 12 | $0.00 |
| 86923 | 0% | 143 | $0.00 | |
| 83516 | 0% | 14 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 364 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 109 | $0.00 |
| 82009 | 0% | 82 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 117 | $0.00 |
| 87075 | 0% | 106 | $0.00 | |
| 12011 | 0% | 16 | $0.00 | |
| 86431 | 0% | 457 | $0.00 | |
| 62323 | 0% | 28 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 29 | $0.00 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 0% | 32 | $0.00 |
| 83020 | 0% | 26 | $0.00 | |
| 51701 | 0% | 58 | $0.00 | |
| J0897 | Injection, denosumab, 1 mg | 0% | 17 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 41 | $0.00 |
| 86200 | 0% | 12 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 18 | $0.00 |
| 86480 | 0% | 12 | $0.00 | |
| 80164 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOGAN, MATTHEW (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Self Medical Group | Greenwood, SC | $6.00M |
| Self Medical Group | Greenwood, SC | $3.28M |
| Self Medical Group | Greenwood, SC | $2.61M |
| Self Regional Healthcare | Greenwood, SC | $2.32M |
| Self Medical Group | Laurens, SC | $2.19M |
| Self Regional Healthcare | Greenwood, SC | $1.68M |
| Self Regional Healthcare Partners | Edgefield, SC | $1.57M |
| Abbeville County Memorial Hospital | Abbeville, SC | $1.42M |
| Abbeville County Memorial Hospital | Abbeville, SC | $1.13M |
| Self Medical Group | Greenwood, SC | $1.05M |
| Self Regional Healthcare Partners | Edgefield, SC | $997K |
| Self Medical Group | Laurens, SC | $806K |
| Abbeville County Memorial Hospital | Due West, SC | $751K |
| Self Medical Group | Greenwood, SC | $721K |
| Self Medical Group | Ware Shoals, SC | $534K |
| Self Medical Group | Saluda, SC | $489K |
| Self Medical Group | Greenwood, SC | $462K |
| Self Medical Group | Saluda, SC | $403K |
| Abbeville County Memorial Hospital | Abbeville, SC | $375K |
| Self Medical Group | Newberry, SC | $319K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.